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Abstract
Background: Time-resolved volumetric magnetic resonance imaging (4DMRI) offers the potential to analyze 3D
motion with high soft-tissue contrast without additional imaging dose. We use 4DMRI to investigate the interplay
effect for pencil beam scanning (PBS) proton therapy of pancreatic cancer and to quantify the dependency of
residual interplay effects on the number of treatment fractions.
Methods: Based on repeated 4DMRI datasets for nine pancreatic cancer patients, synthetic 4DCTs were generated
by warping static 3DCTs with 4DMRI deformation vector fields. 4D dose calculations for scanned proton therapy
were performed to quantify the interplay effect by CTV coverage (v95) and dose homogeneity (d5/d95) for
incrementally up to 28 fractions. The interplay effect was further correlated to CTV motion characteristics. For
quality assurance, volume and mass conservation were evaluated by Jacobian determinants and volume-density
comparisons.
Results: For the underlying patient cohort with CTV motion amplitudes < 15 mm, we observed significant
correlations between CTV motion amplitudes and both the length of breathing cycles and the interplay effect. For
individual fractions, tumor underdosage down to v95 = 70% was observed with pronounced dose heterogeneity
(d5/d95 = 1.3). For full × 28 fractionated treatments, we observed a mitigation of the interplay effect with increasing
fraction numbers. On average, after seven fractions, a CTV coverage with 95–107% of the prescribed dose was
reached with sufficient dose homogeneity. For organs at risk, no significant differences were found between the
static and accumulated dose plans for 28 fractions.
Conclusion: Intrafractional organ motion exhibits a large interplay effect for PBS proton therapy of pancreatic
cancer. The interplay effect correlates with CTV motion, but can be mitigated efficiently by fractionation, mainly
due to different breathing starting phases in fractionated treatments. For hypofractionated treatments, a further
restriction of motion may be required. Repeated 4DMRI measurements are a viable tool for pre- and post-treatment
evaluations of the interplay effect.
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Introduction
Pancreatic cancer is one of the leading causes of cancer
deaths and shows a low 5-year survival rate of 5–20%,
depending on stage at diagnosis [1, 2]. Currently, surgery
remains the only potential possibility for curative
treatment in localized disease, whereas radiotherapy
(RT) and chemotherapy or combinations of both are
used to improve patient survival in unresectable locally
advanced stage.
Nevertheless, new RT techniques are considered more
effective [3].
RT treatments of the pancreas are challenging due to
the limited tolerance doses of adjacent organs at risk
(OARs). While intensity-modulated radiation therapy
(IMRT) is already able to decrease the doses to the
GI-tract and the liver compared to 3D-conformal RT
[4], particle therapy is a more promising modality to fur-
ther reduce OAR toxicity by making use of the physical
characteristics of the “Bragg-peak” [5]. Several encour-
aging preliminary results have been reported from clin-
ical trials using carbon ions [6, 7] or proton radiotherapy
with concomitant chemotherapy [8, 9].
However, the advantages of a high spatial accuracy in
particle therapy are partly counteracted by various types
of uncertainties, especially in the presence of intrafrac-
tional respiration-induced organ motion, which may lead
to density changes in the proton beam paths. These
changes are known to potentially cause heterogeneous
dose distributions in the tumor and over- or undershoot-
ing of the target [10, 11].
For pencil beam scanning (PBS) particle therapy [12],
the resulting interplay effects [13] between beam and
tumor are considerable. Interplay effects have been
investigated for different anatomical sites, such as lung
[14] and liver tumors [15, 16], and various motion
management techniques (e.g. rescanning, gating,
breath-hold) have been proposed and analyzed [17–19]
to mitigate the impact of motion. Nevertheless,
compared to lung tumors whose motion can reach
amplitudes of up to 53mm [20], pancreatic motion is
comparable to liver motion and therefore smaller due to
the increased distance to the lung region [21]. However,
since stomach and bowel filling influence the pancreas
position in general, day-to-day pancreatic motion
variations may occur.
Therefore, in this study it was the aim to evaluate the
interplay effect using repeated time-resolved volumetric
magnetic resonance imaging (4DMRI) for PBS proton
therapy of pancreatic cancer. This approach allowed us
to take into account both intra- and interfractional
patient-specific organ motion and motion variations
without exposing the patients to any additional imaging
dose. We performed 4D dose calculations to quantify
the interplay effect. The dosimetric analysis was based
on synthetic 4DCTs, which were generated by warping
static patient CTs by means of deformation vector fields,
extracted from repeated 4DMRI data sets of patients.
Such an approach was initially developed for liver [22]
and then utilized for one pancreas case in a
proof-of-principle study [23]. In this previous methodical
paper, we showed the feasibility of the synthetic 4DCT
approach for pancreatic cancer, demonstrated the
method by evaluating the statistical evolution of the
interplay effect as a function of treatment fractionation
and reported on the mitigation of the interplay effect by
fractionation for one example pancreas case. However,
due to the lack of statistics, it was not possible to quanti-
tatively conclude on the dosimetric impact of pancreas
motion, the number of required treatment fractions for
an acceptable mitigation, the impact of the interplay
effect on organs at risk and its correlations to tumor
motion characteristics. In another recent study, which
investigated the interplay effect for a cohort of 14
pancreatic cancer patients based on single 4DCTs for
proton or carbon ion treatments [24], it was only
possible to report the magnitude of interplay effect in a
single fraction. Consequently, the efforts of the two
last-mentioned studies were combined here, to evaluate
9 pancreatic cancer patients through the novel 4DMRI
procedures with up to six repeated 4DMRI data sets per
patient. Such repeated 4D data sets enabled a longitudinal
analysis of the interplay effect as a function of the number
of treatment fractions. In this study, we first aimed to
quantify the patient-specificity of both day-to-day motion
variations and the fractionation-induced interplay mitiga-
tion on the planned target dose and OARs. Second, we
statistically determined the interplay impact on organs
at risk and evaluated correlations and factors that in-
fluence the magnitude of the interplay effect. Finally,
we investigated the clinical applicability of our
approach with respect to a possible 4DMRI-based
pre-treatment estimation of the evolution of the
interplay effect along the treatment course.
Material and methods
Patient data
This study comprises a cohort of 9 pancreatic cancer pa-
tients, (6 females, 3 males) with a mean age of 65.9 years
(50–82 years), who received either proton or carbon ion
beam therapy at the Heidelberg Ion-Beam Therapy
Center (HIT). Written informed consent for proton/car-
bon treatment and repeated MR imaging for positioning
control as an individual treatment approach was ob-
tained from all patients. For each patient, a 3D treat-
ment planning CT, acquired under free breathing, was
available on which the gross tumor volume (GTV), the
clinical target volume (CTV), the internal target volume
(ITV), the planning target volume (PTV) and the OARs
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were defined [25]. The GTV and CTV were delineated
by a radiation oncologist, whereas the ITV was gener-
ated by means of the union of all CTVs within all
breathing phases of an acquired 4DCT measurement.
The PTV was defined by adding an isotropic margin of
5 mm around the ITV.
The 4DMRI data were acquired at a 1.5 T MR scanner
(Magnetom Aera, Siemens Healthcare, Erlangen,
Germany), using a T1-weighted gradient echo sequence
with radial stack-of-stars sampling and subsequent itera-
tive 4D-reconstruction, based on a k-space-center
self-gating signal [26]. A wooden flat table top was used
at the MR scanner to ensure a reproducible positioning
of the patient during imaging and treatment. The indi-
vidual settings and parameters for the respective pa-
tients, as well as the time between the acquired 4DMRI
scans can be found in Table 1. Up to six 4DMRI scans
were acquired along the respective patient treatment
course per patient.
The numbers of acquired 4DMRI scans per patients
differed in our cohort since some patients were treated
with carbon ions within 3 weeks whereas others had pro-
ton irradiations over 5–6 weeks and thus were available
for more MRI scans. In addition, MR scanning time cap-
acities did not allow a weekly MR scan in every patient.
All patients except P8 were treated with two oblique
posterior beams. P8 was treated from anterior with only
one field (340°), however, to allow a better comparison
with the results for the other patients, a second field
with 20° was included in the calculations for this patient.
For patients with less than five available 4DMRI data
sets, the length of the breathing cycle of the available
4DMRI data was artificially varied between 3 and 10 s
such as to generate different motion inputs (m) for the
subsequent 4D dose calculation and thereby simulate
day-to-day motion variations. The respective number of
motion inputs (m) for each patient is listed in Table 2.
For the simulated breathing cycles, parentheses are
added in which the respective underlying input motion
is given, e.g. 3.0 (m1) is the 4DMRI data set of measure-
ment 1, where the breathing cycle was changed to be
T = 3.0 s.
Synthetic 4DCT from 4DMRI
The workflow, starting from 4DMRI data acquisition to
the final 4D dose calculations for fractionated PBS
proton therapy, is illustrated in Fig. 1. In short, for each
patient, synthetic 4DCTs, called 4DCT(MRI) in the
following, were generated by warping a 3D treatment
planning CT of the respective patient with deformation
vector fields (DVFs), extracted from 4DMRI data. The
end-exhalation breathing phase EEX of each 4DMR
image was registered to all other breathing phases j of
the same measurement (20 breathing phases in total) by
means of deformable image registration (DIR), using the
open-source software plastimatch (www.plastimatch.org)
and the Demons algorithm [27]. In detail, the ITK
implementation of the demons algorithm, using
fast-symmetric-forces, was used with four different
plastimatch stages and different scales of resolution and
demons step lengths. The 3D planning CT was rigidly
registered to the EEX MR image and the DVFs were
used to deform the 3DCT to obtain a synthetic
4DCT(MRI) for each 4DMRI data set. The workflow is
described in further detail in [23].
CTV motion analysis and deformation field QA
The CTV motion was extracted from the 4DCT(MRI) by
applying a binary CTV mask to the DVFs which results in
motion distributions of all voxels within the CTV delinea-
tion for each breathing phase with respect to EEX.
For DIR quality assurance, Jacobian determinants were
calculated inside the OAR delineations (liver, kidneys,
bowel) for each 4DCT(MRI), using the DVF between
Table 1 Number of available 4DMR images, patient positioning, beam angels of both fields (F0, F1), CTV volume and time between
consecutive 4DMRI data sets
Patient # 4DMRI Positioning Beam angle [°] CTV volume [cc] Time between consecutive
4DMRI scans [days]
F0 F1
P1 2 supine 160 210 51.9 1
P2 6 supine 160 210 33.0 15 / 5 / 9 / 3 / 10
P3 5 supine 160 210 95.1 6 / 9 / 5 / 11
P4 2 prone 20 340 87.8 21
P5 1 prone 20 340 194.8 –
P6 1 prone 20 340 115.1 –
P7 1 supine 160 200 112.0 –
P8 3 supine 20 340 62.4 15 / 24
P9 2 prone 20 340 46.0 7
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the EEX and end-inhalation breathing phase EIN to
evaluate volume conservation.
With respect to mass conservation, the delineated
volume VEEX of each OAR on the EEX phase of each
4DCT(MRI) was multiplied by the estimated physical
density ρEEX for each voxel inside the delineation, ob-
tained from a generic HU-to-density lookup table [28],
to obtain the respective mass mEEX. Then, mEIN =VEIN ·
ρEIN was calculated with VEIN being derived by warping
the OAR delineation from EEX to EIN using the respect-
ive DVF and the respective density information ρEIN. Fi-
nally, the ratio mEEX/mEIN was considered as an estimate
of mass conservation.
Treatment planning and 4D dose calculation
For all patients, PBS proton therapy plans were used
with 1.8 Gy (RBE) per fraction (RBE = 1.1) and 28
fractions, employing the beam angles of the treatments
that had actually been delivered, see Table 1.
A 3D single field uniform dose (SFUD) plan with two
fields for PBS proton therapy was calculated on the
3DCT for each patient. 4D dose calculations were
performed by means of the PSI 4D pencil beam proton
dose calculation algorithm [22, 29], taking into account
the density changes, extracted from the 4DCT(MRI), the
respective breathing cycle T for motion input m (see
Table 1) and the beam dynamics of the PSI-Gantry2
[18], e.g. the time stamps and weights of each individual
pencil beam. For each field, the 4D dose distributions
for 20 different initial breathing starting phases of the
patient, derived from the 20 available different breathing
phases of each 4DMRI data set, were calculated.
For every fraction of the simulated 28 fraction PBS
proton treatments, such a 4D dose distribution was
calculated by random selection of both the underlying
Table 2 Number of input motion patterns m for the 4D dose calculation and respective breathing cycles T [s] for P1-P9
P1 P2 P3 P4 P5 P6 P7 P8 P9
m1 7.1 3.8 9.7 3.7 3.7 5.6 3.0 (m5) 4.7 3.7
m2 3.0 (m1) 2.8 8.2 3.0 (m1) 3.0 (m1) 3.0 (m1) 5.0 (m5) 3.0 (m1) 3.0 (m1)
m3 5.5 (m1) 3.7 8.8 5.5 (m1) 5.5 (m1) 5.5 (m1) 7.0 (m5) 10.0 (m1) 5.5 (m1)
m4 10.0 (m1) 3.7 8.4 8.0 (m1) 8.0 (m1) 8.0 (m1) 9.0 (m5) 5.6 2.9
m5 4.8 3.7 6.7 5.9 10.0 (m1) 10.0 (m1) 10.0 3.0 (m4) 3.0 (m4)
m6 3.0 (m5) 2.8 3.0 (m5) 10.0 (m4) 5.5 (m4)
m7 5.5 (m5) 5.5 (m5) 5.6
m8 10.0 (m5) 10.0 (m5) 3.0 (m7)
m9 10.0 (m7)
Fig. 1 Schematic Workflow from 4DMRI via synthetic 4DCT(MRI) to 4D dose calculations for fractionated PBS proton therapy of pancreatic cancer
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4DCT(MRI)m density information and the breathing
starting phases (i, k) for both fields F0 and F1, see Fig. 1.
The resulting interplay effect was analyzed with
respect to dose homogeneity in the CTV (d5/d95), CTV
coverage (v95, v107), mean dose dmean and near max-
imum dose d2 in the CTV for the 3D dose calculation
(3DDC), as well as for the 4D dose distributions for sin-
gle fractions (4Dx1) and 28 fractions (4Dx28), respect-
ively. Here, d5, d95 and d2 denote the relative doses that
5, 95 and 2% of the volume receive, respectively, and v95
and v107 are the percentage volumes, that receive at
least 95 and 107% of the prescribed dose.
Moreover, the dose-volume-histograms (DVHs) for
OARs, namely left/right kidney, spinal cord, liver and
bowel were analyzed with respect to dmean, d2 and v30,
where v30 denotes the volume that receives at least 30%
of the dose. The results were tested for significance by
means of a single-sided Wilcoxon rank-sum test with a
confidence level of 95% (α = 0.05).
Correlation analysis
Inter-patient correlations between CTV motion ampli-
tudes, length of breathing cycles and the interplay effect,
assessed as d5/d95 of a single fraction, were determined
by calculations of weighted correlations coefficients ρw.
The respective numbers of repeated 4DMRI data sets
were used as weights for each patient, in compliance
with previous publications [30, 31].
The statistical significance was calculated assuming a
t-distribution of the data for small sample sizes with N = 9.
In this case, the test statistic t ¼ ρw 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃðN−2Þ=ð1−ρ2wÞ
p
was
calculated and compared to the tabulated critical
value tcrit = 1.833 of the t-distribution for a one-sided
test with a confidence level of 95%. Statistical signifi-
cance was determined for t > tcrit.
Furthermore, the correlation coefficient ρm between
CTV volumes, which were considered constant for all
fractions, and the mean interplay effects were calculated.
The dependency of patient positioning (supine/prone)
and beam angles on the interplay effect was analyzed by
comparison of mean d5/d95 values. Additionally, for
patients with multiple available 4DMRI data sets,
intra-patient dependencies between CTV motion ampli-
tudes, length of breathing cycles and the interplay effect
(d5/d95) were analyzed.
Longitudinal interplay investigation for a possible clinical
application
In a possible clinical scenario, pre-treatment acquisitions
of 4DMRI data sets could be used to estimate the statis-
tical evolution of the interplay effect during fraction-
ation. We investigated the uncertainty of such an
estimation based on a single pre-treatment 4DMRI as
opposed to multiple 4DMRI data sets acquired over the
treatment course by comparing the respective evolu-
tion of the interplay effect, assessed as d5/d95. For all
patients with ≥2 available 4DMRI scans (P1, P2, P3,
P4, P8, P9), we performed 30 simulations each of the
entire × 28 fractionated treatment scheme, taking into
account only the first motion pattern (m1) to simu-
late a single pre-treatment 4DMRI acquisition, or all
motion patterns, respectively. For the latter, for each
treatment fraction the respective motion pattern was
randomly sampled from the available patterns for
each patient.
Results
Motion extraction from 4DMRI and vector field QA
The extracted CTV motion distributions in inferior-su-
perior (IS), anterior-posterior (AP) and left-right (LR)
direction are illustrated in Fig. 2 for all patients. They
show the patient-specificity of the motion patterns as
well as interfractional changes in CTV motion, ex-
tracted from the 4DCT(MRI). For this patient cohort,
maximum CTV motion amplitudes of 15 mm were
present with comparably small mean values of ≤8 mm in
IS and ≤3 mm in AP and LR direction, respectively.
Maximum intra-patient day-to-day differences in mean
and maximum motion amplitudes of up to 5.3mm and
8.1 mm (for P8), respectively, arose in IS direction, the
dominant direction of motion.
The evaluation of volume and mass conservation
yielded a mean Jacobian determinant among all patients
of 1.00 ± 0.04, indicating volume-conserving DIR with
low regional volume changes in the OARs. A mean mass
conservation coefficient value of mEEX/mIN = 1.07 ± 0.05
was derived.
Static treatment plans
The 3D SFUD plans revealed an average mean dose of
dmean = 99.6% (range 99.5–99.9%) with full CTV cover-
age (v95 = 100%, v107 = 0%), high dose homogeneity
with d5/d95≤1.03 (range 1.01–1.03) and near maximum
dose values of d2 < 103% (range 100.3–103.0%) for 8 out
of the 9 patients. For P8, slightly inferior values
(dmean = 101.4%, v95 = 100%, v107 = 6.5%, d5/d95 = 1.11,
d2 = 108.9%) were obtained, as illustrated in Fig. 3a, c, d.
4D dose distributions for single fraction
By means of 4D dose calculations of a single fraction
(4Dx1), the interplay effect of all combinations of initial
breathing starting phases and underlying motion
patterns was quantified in terms of d5/d95 and v95.
Depending on the patient, mean d5/d95 = 1.05–1.14
were obtained with maximum values of up to 1.3. CTV
coverage v95 mean values of 92–100% were observed
with minimum values of 70%, implying pronounced
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underdosage of the CTV. Moreover, near maximum
doses d2 of up to 110% were present within the CTV.
These values show a strong dependency on the under-
lying motion input, which is discussed in detail in
“Correlation analyses” section below. The calculated 3D
SFUD plans, exemplary single fraction 4D dose distribu-
tions and single fraction interplay effects in terms of d5/
d95 and v95 are displayed in Fig. 3. Pronounced hot and
cold spots are visible in the 4D distributions.
4D dose distributions for 28 fractions treatment
The simulated treatments with 28 fractions (4Dx28)
show a patient-specific mitigation of the interplay effect
as a function of the number of treatment fractions.
Figure 4 displays example d5/d95 and v95 values for
patients P1/P2/P6, who showed large/medium/small
interplay effects in the single fraction calculations, re-
spectively. Mean d5/d95 decreased from 1.13/1.09/1.05
to 1.03/1.03/1.02 for these patients after 28 fractions,
mean v95 reaches 100% after 11/6/2 fractions,
respectively.
We observed the same trend of an increased averaging
effect of the interplay effect as a consequence of an in-
creased number of fractions for all patients in this study.
After a standard fractionation scheme with 28 fractions,
the dose homogeneity d5/d95 in the CTV was similar
for both 4D and 3D dose distributions and v95 = 100%
was obtained for all patients after 2–14 fractions (mean:
6.7 fractions). Moreover, d2 as well as v107 were
reduced by fractionation. Except for P8, v107 = 0% was
obtained after at most 10 fractions (mean: 5.6 fractions).
For P8, v107 = 6% was observed after 28 fractions.
On average, dmean increased by 0.47%/0.49% in the
4DDC for 1 or 28 fraction scenarios, respectively, com-
pared to 3DDC. For d5/d95, d2 and v107, we observed
significantly higher values for 4Dx1 compared to both,
3DDC and 4Dx28, whilst v95 was significantly lower for
4Dx1 compared to both 3DDC and 4Dx28, as apparent
in Fig. 5.
With respect to dmean and d5/d95, statistically signifi-
cant differences between 3DDC and 4Dx28 were
observed, which, however, appear to be clinically less
relevant due to the small absolute differences (mean
dmean = 99.8% / 100.3% and mean d5/d95 = 1.028/1.034
for 3DDC/4Dx28, respectively). These results indicate
that statistically for a large number of fractions, the
interplay effect reduces to an acceptable CTV dose
distribution in PBS proton therapy of pancreatic cancer.
Dose to OARs
From the DVHs for the left/right kidney, spinal cord,
liver and bowel, the dose quantities dmean, d2 and v30
were compared among 3DDC, 4Dx1 and 4Dx28. The
deviations in dmean were < 0.5% for all considered organs
at risk. With respect to mean v30, deviations of < 1.2%
were observed between the three different scenarios.
The mean near maximum dose d2 increased by 0.6–
3.2% for all OARs (except in the bowel, where d2
decreased by 1.5–2.1%) when comparing 3DDC with
both 4Dx1 and 4Dx28. Overall, no significant differences
were found for the OARs, comparing the three different
scenarios, see Fig. 6.
Correlation analyses
The analysis of inter-patient correlations showed signifi-
cant (t > tcrit = 1.833) positive correlations between CTV
motion amplitudes on the one hand, and the length of
breathing cycles and the interplay effects assessed in
terms of d5/d95 on the other hand, as illustrated in
Fig. 7. The strongest correlation was revealed between
the CTV motion amplitudes and d5/d95 (ρw = 0.86, t =
4.46). Smaller, but still significant correlations were
found between breathing cycle and CTV motion ampli-
tude (ρw = 0.65, t = 2.26). The correlations between the
length of breathing cycles and d5/d95 (ρw = 0.48, t = 1.45)
and between CTV volume and d5/d95 (ρm = − 0.49,
t = 1.49) were determined to be not significant.
Fig. 2 Motion distributions of all voxels inside the CTV delineation between end-inhale and end-exhale breathing phases for P1-P9 in a IS, b AP
and c LR direction for the respective numbers of available 4DMRI data sets. The whiskers indicate the 95% range of the boxplots
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Patients in supine positioning (mean d5/d95 = 1.10)
showed a similar magnitude of interplay effect as
patients in prone positioning (mean d5/d95 = 1.08).
The intra-patient analysis revealed patient-specific
both proportional and anti-proportional dependencies
between CTV motion amplitude, interplay effect and
length of breathing cycles with no clear tendency. Due
to the small sample sizes, no correlation coefficients
were determined.
Longitudinal interplay investigation towards a possible
clinical application
For a pre-treatment estimation of the statistical evolu-
tion of the interplay effect during a × 28 fractionated
treatment scheme, we found that a single 4DMRI
scan may be sufficient for patients with low
day-to-day motion variations, which was the case in
this study (day-to-day variations of mean motion am-
plitudes ≤5.3 mm ). Due to the interplay mitigation
effect by variable initial breathing phases in different
fractions, after 28 fractions the mean d5/d95 value in
4D simulations with a single underlying 4DMRI or all
available 4DMRI scans for the respective patients dif-
fered only by 0.1%. For smaller numbers of fractions
(< 5), the estimation of the interplay effect by the
single-4DMRI approach differed by up to 3% com-
pared to the multiple-4DMRI approach. Figure 8 il-
lustrates both scenarios for P2 and P8.
Fig. 3 a 3D SFUD plans and b exemplary 4D dose distributions for single fraction PBS proton therapy (4Dx1) of patients P1-P9 with the respective
delineations of CTV/PTV in black/pink. Doses below 90% of the prescribed dose are not displayed in this dose representation. The blue arrows indicate
the beam angles. The interplay effect in terms of c homogeneity index d5/d95 and d v95 for all patients are displayed for n calculated possible 4D
dose scenarios of single fraction treatments with variable initial breathing phases. The green crosses indicate the values of the static 3D case
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Fig. 4 Exemplary d5/d95 (a-c) and v95 (d-f) distributions for 1–28 fractions PBS proton therapy of pancreatic cancer for P1/P2/P6, who showed a
large/medium/small interplay effect. The green lines indicate the static 3D case
Fig. 5 CTV dose quantities (dmean, d2, d5/d95, v95, v107) for P1-P9, resulting from 3D dose calculations (3DDC), as well as from 4D dose
distributions for single (4Dx1) and 28 fractions (4Dx28), respectively
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Discussion
This study shows a pronounced averaging effect of the
interplay effect by means of fractionation for a cohort of
9 pancreatic cancer patients. On average, after 7
fractions (range 2–14), a sufficient CTV coverage of
95–107% was obtained. This result is especially
interesting with respect to hypofractionated treat-
ments, as for instance performed in a Japanese
carbon-ion dose escalation study with 8 fractions,
which showed nevertheless promising outcomes [32].
However, although fractionation leads to a mitigation
of the interplay effect, still in every single fraction hot
and cold spots occur, whose clinical impact should be
evaluated separately. For hypofractionated treatments
or large motion amplitudes, additional motion mitiga-
tion could for instance be achieved by means of
abdominal corsets [33, 34]. Alternatively, the choice
of suitable small gating windows could further
improve the resulting dose distributions and is of
interest for further studies.
With respect to correlations, we found strong and
medium positive inter-patient correlations between the
CTV motion amplitudes on the one side and both the
length of breathing cycles and the interplay effect on the
other side, which is in good agreement with Dowdell et
al., who found similar correlation for the interplay effect
in lung proton treatments [35]. We are aware that our
patient cohort shows comparably low CTV motion
amplitudes, whereas pancreas motion amplitudes of >
30 mm have been reported [36]. From the observed
correlations between CTV motion amplitudes and the
amount of interplay effect, we therefore expect a
stronger impact of the interplay effect for
large-motion patients than for our patient cohort.
We need to acknowledge several limitation in our
study here. First, deformable dose mapping is generally
limited by uncertainties resulting from the performed
image registrations and the resulting VFs [37, 38]. The
VF-QA, performed in this study, showed sufficient
Jacobian determinant values of 1.00 ± 0.04. In terms of
mass conservation, it has been pointed out, that deform-
able image registrations in general may show certain
uncertainties concerning mass conservation, since CT
Hounsfield Units may be averaged during transform-
ation [39]. We observed relative mass differences in
the considered OARs between the EIN and EEX im-
ages of 7 ± 5%. Similar mean deviations of 5 ± 7% have
been reported for DIR of thoracic CTs with deviations
up to 50% [40], which illustrate the intrinsic uncer-
tainties of deformable image registration.
Second, the demonstrated method of warping a static
CT by means of various 4DMRI vector fields holds
further intrinsic limitations. Geometrical differences in
the patient anatomy between different days, such as
Fig. 6 The OAR dose quantities a dmean, b d2 and c v30 show no significant differences when comparing static dose calculations (3DDC) with 4D
scenarios with single (4Dx1) and 28 fractions (4Dx28). Exemplary DVHs of P5 for d 4Dx1 and e 4Dx28 include both OARs and the CTV, as well as
the respective dosimetric results from the 3D dose calculations in dashed lines
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translations of pancreas due to gastrointestinal disten-
tion [41], are not fully considered in this 4D treatment
planning approach, as the same patient CT is deformed
for all of the various motion inputs of the same patient.
Moreover, the free-breathing treatment planning CTs
were registered to the EEX phase of the respective
4DMR images, which visually showed a better agreement
to the CT than the mid-ventilation MR images. However,
a detailed statistical analysis to determine the most suit-
able of all available 20 breathing phases of each 4DMRI
could further reduce the registration uncertainties. Alter-
natively, a more challenging deformable multi-modal
CT-MR deformable image registration could be consid-
ered in future studies.
Furthermore, only regular breathing motion was inves-
tigated. The impact of irregular motion pattern on the
interplay mitigation should be investigated in future
studies. For the simulated 4D data sets we did not
change the motion amplitudes when varying the length
of breathing cycles due to the unclear intra-patient
correlations between CTV motion amplitudes and
length of breathing cycles. However, it is unclear
whether the amplitudes would indeed be the same for
different lengths of breathing cycles, which is a limita-
tion of this study.
Finally, we would like to rephrase the importance and
advantages of using repeated 4DMRI data sets of
patients for subsequent 4DCT(MRI) generation and 4D
dose calculation, compared to the conventional 4DCT
approach. Being an imaging modality without any imaging
dose to the patient, regular 4DMRI data could be acquired
from the patients, saving 20–200mGy compared to a sin-
gle 4DCT measurement [42]. By means of 4DMRI data,
the duration of data acquisition may be extended over mul-
tiple breathing cycles, which provides more information
than a single 4DCT snapshot of a single breathing cycle.
Fig. 7 Inter-patient correlations between CTV motion amplitudes, length of breathing cycles and the interplay effect assessed as d5/d95 (a-c).
For each patient, the mean values of the respective quantities are displayed. The correlation between the interplay effect and the CTV volume is
illustrated in (d)
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Previous studies have shown that pancreas motion
shows huge day-to-day variations and one single 4DCT
may not be representative for the tumor motion during
a treatment [43], lasting over several weeks. Repeated
4DMRI measurements, acquired prior to the treatment,
can help to observe these motion variations and could
potentially be used for robust analyses or worst-case
optimizations [44], based on real patient-specific motion
patterns. In future scenarios, if online 4DMRI is
available during irradiation on hybrid MR-Linac devices
[45–48] or possible MR-proton devices, such an ap-
proach can also be used for online 4DMRI-based dose
recalculations. For instance, static MR images could be
acquired prior to each fraction to account for geomet-
rical differences and patient setup errors. Then, 4DMRI
could be acquired simultaneously during each irradiation
fraction and the derived vector fields could be used to
retrospectively calculate a 4D dose distribution of the
day by means of the proposed method in this study and
to accumulate all 4D fraction doses.
Even without online MR image-guidance, we found
that our proposed method to quantify the interplay
effect as a function of fractionation provides a viable tool
for pre-treatment estimations of the statistical evolution
of the interplay effect within an uncertainty range of a
few percent for patients with low day-to-day motion
variations. This is due to the fact, that variable initial
breathing phases during irradiation fractions have a
larger impact on the mitigation effect than small differ-
ences in breathing motion patterns. Therefore, such an
approach allows an estimation of the statistical mitiga-
tion of the interplay effect by means of pre-treatment
4DMRI acquisitions. Based on such pre-treatment
4DMRI data, criteria may be defined to determine,
whether additional motion limitation by abdominal
compression or the application of gating criteria may be
required for a specific patient.
Conclusion
We found 4D dose evaluation, based on repeated 4DMRI
data sets, to be a promising methodology to investigate
the mitigation of the interplay effect in PBS proton ther-
apy of pancreatic cancer treatments. 4D investigations of a
patient cohort of 9 pancreatic cancer patients with CTV
motion amplitudes < 15mm showed significant positive
correlations between CTV motion amplitudes one the
one hand and both the interplay effect and the length of
breathing cycles on the other hand. We observed a grad-
ually increased mitigation of the interplay effect with an
increased number of fractions. After an average of 7 frac-
tions, a sufficient CTV coverage of 95–107% was observed
and the dose homogeneity within the CTV was similar in
3D and 4D dose distributions. For hypofractionated treat-
ments, the study indicates a more pronounced impact of
the interplay effect for pancreatic cancer treatments. For
patients with low day-to-day motion variations, such as
those enrolled in this study, the statistical evolution of the
interplay effect along the treatment course could be
estimated based on a single 4DMRI.
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